Login to Your Account



Entasis phase III antibiotic to take on world gonorrhea threat

By Randy Osborne
Staff Writer

Friday, July 7, 2017

In previous antibiotic drug development, "you would always look for the one molecule and the one dose that you could use for everything," Entasis Therapeutics Inc. CEO Manos Perros told BioWorld.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription